Abstract
GnRH therapy is useful for the treatment of various diseases, such as prostate cancer, endometriosis, uterine leiomyoma, based on its reduction of sex steroids. However, it causes osteopenia with high bone turnover in the mechanism similar with ovariectomy or castration. Bisphosphonate potently inhibits bone resorption, which subsequently inhibits elevated metabolic bone markers and osteopenia by GnRH therapy. The intravenous administration of pamidronate markedly inhibited osteopenia induced by GnRH therapy in some reports, but further study is necessary about the usage of bisphosphonate for osteopenia accompanied by GnRH therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
